starpharma

Tony Eglezos VP Business Development

STARPHARMA DEP™ Drug Delivery

> PODD 2016 - Boston 27-28 October



This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

Overview: Starpharma Holdings Limited (ASX:SPL)

- ASX 300 company (ASX:SPL, OTCQX:SPHRY) located in Melbourne, Australia
- Market Cap ~ A\$250M
- Deep product portfolio of commercial and late stage products based on novel polymer (dendrimer) platform
- Developing first-in-class (new) therapies through a highly experienced in-house commercialisation team
- Established commercial partnerships with some of the world's leading companies - accelerates product development, shares development risk, and transfers development costs
- Strong cash position (\$46M 30/6/16)




Starpharma's headquarters and laboratories Melbourne, Australia

A global leader in dendrimer products

starpharma

Starpharma's portfolio includes multiple commercial partnerships with leading companies





DEP[™] Drug Delivery Platform

- DEP[™] dendrimer (nanoparticle) delivery technology shows broad commercial applicability
- Internal development and partnered program allows for accelerated development and increased returns
- Applicable to both currently marketed/generic and proprietary pharmaceuticals
- Potential across multiple diseases cancer, inflammation, diabetes
- High commercial value opportunity, significant optionality via multi-product application

DEP™ Product Portfolio			Research	Pre- clinical	Phase I	Phase II	Phase III	Reg approval
Oncology (Internal)	Drug Delivery	DEP™ docetaxel (various cancers)				\rightarrow		
	Drug Delivery	DEP™ oxaliplatin DEP™ cabazitaxel DEP™ TDCs						
	Drug Delivery	Various Oncology DEP™						
Partnered programs	Drug Delivery	DEP™ Delivery – oncology, diabetes etc.			As	straZe	neca	

Planned

Completed

starpharma

DEP™ Drug Delivery



Starpharma's DEP™ Platform – Flexible, Scalable, Precise

DEP[™] dendrimer

- Clinically validated
- Easily scalable; precisely manufactured

Drug/Payload

 Payload flexibility – type and number

Linkers


• Tuneable to meet payload release requirements


PEG

- Provides stealth
- Controls clearance


Targeting (optional)


- Sites specific attachment
- Targeting moiety flexibility





24 hr





168 hr


DEP[™] docetaxel accumulation in tumour



Dual Strategy

Provides technical, IP and financial leverage Increases commercial opportunities Reduces invested capital De-risks





Extensive partner engagement to maximise commercial outcomes






Starpharma's DEP[™] Delivery License with AstraZeneca (LON:AZN)

	1
	1
	1
	1
	1
444	1
tornharma	1
starphone	1
	1
	1
	1
	1
	1
A ANNOUNCEMENT	1
ACX ADDIAL CONT	1
AdraZeneta	
to the Will Conse with Party	
Starpharma signs drug delivery license with AstraZeneca Starpharma signs drug delivery license with AstraZeneca AstraZeneca has signed a licensing agreement with Starpharma for the use of its AstraZeneca delivery platformation of an its development and sommerclaimation of an	
starpharma for the standard and an	
a sing agreement wind commercialisation of	
a bas signed a licenship development and with potential for forest	
Stamharma Signis using AstraZeneca has signed a licensing agreement with Stamharma for the use of mo- DEP [#] drug delivery platform in the development and commercizationation of an DEP [#] drug delivery platform to the development and with potential for follow on DEP [#] drug delivery platform to the development and stampercisation of an operation accology or compound on signature, and with potential for follow on the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development	
	6
 Statistication of an Astroacenesa has signed a licensing agreement with Statistication of an DEP[#] drug delivery platform in the development and commercialisation of DEP[#] drug delivery platform on signature, and with potential for follow on Astroacenes delivers and a defined family of targets. 	
 Attracting delivery platformpound on signature; and Astrazionea anoclogy compound on signature; and Astrazionea anoclogy compounds family of targets; compounds directed at a defined family of targets; compound	
 DEP[#] and delivery pays compound on signature payment of USS2 million compounds directed at a defined family of dragets. Under the agreement Starpharma will receive a signature payment of USS2 million (AS2 million), and is also eligible to receive potential development, launch and (AS2 million), and is also eligible to receive potential development at million is also eligible to receive potential development. 	
under the agreement is also eligible to reach DEP [®] product of Cent	
agles milestones for the milestones to the miles	1.0
(act 77 million).	in .
(Astronomy in the successfully in the second	
the second state of the se	
 Subsected annual sales revealed. 	\$180
Value millestones for une new sales millestones for une new (ASTT million). Subsequent qualifying products successfully developed and commercialised to subsequent qualifying products successfully developed and commercialised to subsequent developed and successfully developed and commercialised to successfully developed and commercialised to subsequent developed and successfully developed and commercialised to subsequent developed and successfully developed and commercialised to successfully developed and commercialised to subsequent developed and successfully developed and commercialised to successfully developed and commercialised to subsequent developed and successfully developed and commercialised to successfully developed an	133
milestone y-1	
signature and mines DEP ⁶ product and op	
Subsequent qualifying press could year up to the specified any must sate previous of the specified any must sate product. Intestone payments per product. In summary, signature and milestone payments could total USD\$125 million (At subsequence) and up to USD\$33.3 million (At subsequence).	e5.
 SUBSTREAM AND A SUBSTREAM A SUBSTREAM AND A SUBST	
million) for each also attract increase	
 In summary, signature to Zenecs DEP product. million) for each subsequent qualifying product. million) for each subsequent qualifying product. Any AstraZenecs DEP products would also attract liced royalties on net sate Any AstraZenecs DEP products under the agreement. Any AstraZenecs DEP products under the agreement. 	
Any Astractive and commercial	
in fund all development.	
AstraZeneca with anducts under the wa	
AntraZeness will fund all development and concernance AstraZeness DEF [®] products under the agreement.	
	_

"SPL estimates that each product successfully commercialised under this agreement could be worth around US\$450m to Starpharma and, depending on the range of indications and degree of commercial success in the market, potentially significantly more"

- AZ multi-product license for use of DEP[™] delivery platform for the development and commercialisation of proprietary AZ compounds directed at a defined family of targets
- SPL eligible to receive development, launch and sales milestones for the first AZ DEP[™] product of up to USD\$126m plus royalties & up to USD\$93m in milestones for each subsequent qualifying AZ DEP[™] products
- Tiered royalties on net sales
- AZ funds all development and commercialisation costs
- DEP[™] docetaxel not impacted and agreement field allows for multiple other DEP[™] licences
- Received US\$2M in H1 FY2016



"We already have a long-standing and successful working relationship with Starpharma. This license agreement will enable us to further harness the DEP™ technology and evaluate its potential across novel molecules within our oncology portfolio."


> Dr Susan Galbraith, Head of the Oncology Innovative Medicines Unit at AstraZeneca



Starpharma's DEP[™] Docetaxel: Multiple Benefits

- Docetaxel (Taxotere[®]) is a blockbuster chemotherapeutic
- Docetaxel sales: US\$3.1B (2012)
- Docetaxel is used in major cancer types including breast, prostate, lung and ovarian cancer
- Starpharma's DEP[™] docetaxel has important advantages compared to Taxotere[®] [#]
- DEP[™] docetaxel patents filed will offer coverage to 2032 (potential for further filings)
- DEP[™] docetaxel Phase 1 trial no neutropenia, hair-loss and promising efficacy signals







1. Elimination of major dose-limiting side

effect (neutropenia)

- 2. Detergent-free formulation (less toxic)
- 3. Tumour targeting (40-70x more)
- 4. Extended duration (half-life)
- 5. Improved efficacy (breast, ovarian,
 - prostate)





Patents filed will offer coverage to 2032 (potential for further filings)



DEP™ Docetaxel Phase 1 Clinical Trial:

Encouraging anticancer activity and no neutropenia

- Ongoing open label study, approx. 25-30 cancer patients (various solid tumours)
- DEPTM docetaxel administered intravenously (no steroid pre-treatment or anti-emetics required unlike Taxotere[®])

Current status :

- Patients dosed up to & above commonly used Taxotere[®] dose of 75mg/m² multiple cycles (up to 6 cycles)
- Final phase of enrolment underway ; >80% recruited
- Large UK site recently opened will enrich final patient cohort with specific tumour types and facilitate transition to Phase 2

Findings:

- No neutropenia (docetaxel dose limiting toxicity) or alopecia (hair loss) reported
 - Compared to Taxotere[®] where severe neutropenia is suffered by 75% of patients dosed 60mg/m²^
- A significant proportion of DEP[™] docetaxel patients have exhibited efficacy signals/anticancer activity
- Efficacy signals for DEP[™] docetaxel seen
 - at low doses and in cancers not typically responsive to docetaxel
 - in pancreatic (SD* > 20 wks), oesophageal (SD > 18wks), prostate, lung, H&N, and brain tumours

Phase 2:

Planning and preparations now well advanced including CRO, trial design, KOLs, sites; clinical trial material manufacture underway




DEP[™] cabazitaxel: significantly improved efficacy in breast cancer model*


Tumour Volume (mm³)

About Cabazitaxel (Jevtana[®])

- 2015 sales: US\$427m (+18%)
- Primary indication Prostate cancer
- In development for various other cancer including breast, bladder, Head and Neck and others
- Dose Limiting Toxicity neutropenia (FDA "Black box" warning)
- FDA "Black box" warning due to anaphylaxis (Polysorbate 80 detergent)



• MDA-MB-231 (human breast tumour) xenograft model in Balb/c nude mice




Tumour Volumes



Targeted DEP™ Conjugates

<u>A flexible approach to drug conjugate</u> <u>design and development</u>



Diagrammatic representation of Herceptin targeted dendrimer conjugates

Starpharma's Ab TDC's provide;

- Greater homogeneity
- Site specific attachment of drug conjugate
- High **affinity**
- The delivery of **significantly higher payload** levels than conventional ADC's

Pilot study to evaluate the efficacy of HER-2 TDC's against ovarian cancer xenografts

Method:


- SKOV-3 tumour model in NOD SCID mice
- s.c. implantation
- Allow tumor to grow to >100mm³
- Treatment groups
 - Vehicle*,
 - Ab Targeted DEP[™] drug conjugates
 - Kadcyla [10mg/kg*]
 - Herceptin [30mg/kg bi-weekly for 3 weeks]
- * Weekly (days 1, 8 and 15) via iv route for 3 weeks at 0.1ml/10g body weight
- 6 animals/group
- Measurement of tumour growth 2-3 times weekly




Targeted DEP™ Conjugates

A flexible approach to drug conjugate design and development

•






SPL's novel HER2-targeted DEP™ conjugate resulted in;

- complete tumour regression and 100% survival in an ovarian cancer model
- significantly outperformed both Roche's Kadcyla[®] (T-DM1) and the monoclonal antibody Herceptin[®] (Trastuzumab) alone

Statistical analysis at day 40. Kadcyla[®] vs Targeted DEP™; P <0.0001. (ANOVA followed by Tukey's post hoc test).

• 2 targeted DEP[™] partnerships signed with major antibody-drug-conjugate players - August 2016





Starpharma's DEP™ platform

A highly versatile platform with significant commercial and therapeutic benefits

			Patent protection /extension	×
Passive Targeting	Active Drug Targeting Enhancement	Commercial	Innovative treatment options	✓
		Benefits	Competitive product advantages	✓
			Robust, scalable manufacturing	√
			Flexible platform with broad applicability in targeted therapies	~
DEP™ dendimer	Precisely manufactured poly-lysine dendrimer (variable size) Manufactured using standard chemistry		Enhanced product properties –	
Toxin/Drug/Payload	Small molecule, Cytotoxic, Ultratoxic		increased solubility; enhanced PK and efficacy; better side effect	\checkmark
 Targeting group 	Whole antibody, fragment, mimetic, small molecule	Therapeutic	profile	
• PEG	Provides stealth; solubility; control clearance; flexibility in size	Benefits		
 Drug to be enhanced Molecule requiring enhanced PK, PD, solubility or elimination of off target toxicities , expansion of therapeutic window 			Greater homogeneity with higher payload ratio than conventional ADC approaches	~
			Enders and the same of the stimulation	1

Enhanced therapeutic window

Patent protection /extension



Contact

Tony Eglezos VP, Business Development Starpharma Pty Ltd

4-6 Southampton Crescent, Abbotsford, VIC 3067 AUSTRALIA

Email: <u>tony.eglezos@starpharma.com</u> Web: <u>www.starpharma.com</u> David Owen VP, Research Starpharma Pty Ltd

4-6 Southampton Crescent, Abbotsford, VIC 3067 AUSTRALIA

Email: <u>david.owen@starpharma.com</u> Web: <u>www.starpharma.com</u>